Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis

Scandinavian Journal of Gastroenterology

Volumn 41, Issue SUPPL. 243, 2006, Pages 79-84

  Van Erpecum, Karel ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Ascites; Cirrhosis; Probiotics; Spontaneous bacterial peritonitis; TIPS

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTRIAXONE; FUROSEMIDE; NORFLOXACIN; PROBIOTIC AGENT; SPIRONOLACTONE; TERLIPRESSIN; ANTIINFECTIVE AGENT; DIURETIC AGENT;

ASCITES; AUTOIMMUNE HEPATITIS; BACTERIAL PERITONITIS; CONFERENCE PAPER; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER INJURY; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; SMALL INTESTINE; BACTERIAL INFECTION; PERITONITIS; REVIEW;

ANTI-BACTERIAL AGENTS; ASCITES; BACTERIAL INFECTIONS; DIURETICS; HUMANS; LIVER CIRRHOSIS; PERITONITIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 33745345854     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600664342     Document Type: Conference Paper

References (27)

1. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998;27:264-72.
2. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-10.
3. Garcia-Tsao G. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Practice and Research Clinical Gastroenterology 2004;18:353-72.
4. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-18.
5. Gines P, Guevara M, Perez-Villa F. Management of hepatorenal syndrome: another piece of the puzzle. Hepatology 2004;40:16-18.
6. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002;122:1658-76.
7. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32 Suppl 1:157-70.
8. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841-56.
9. Spahr L, Villeneuve JP, Tran HK, Pomier-Layrargues G. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. Hepatology 2001;33:28-31.
10. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10.
11. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005;41:386-400.
12. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003;124:634-41.
13. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996;25:135-44.
14. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-7.
15. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47.
16. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629-35.
17. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-75.
18. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-53.
19. Pardo A, Bartoli R, Lorenzo-Zuniga V, Planas R, Vinado B, Riba J, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000;31:858-63.
20. Guarner C, Sola R, Soriano G, Andreu M, Novella MT, Vila MC, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999;117:414-19.
21. Castellote J, Lopez C, Gornals J, Tremosa G, Farina ER, Baliellas C, et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology 2003;37:893-6.
22. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
23. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8.
24. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
25. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8.
26. Fernandez J, Ruiz del Arbol L, Serradila R, Gomez C, Guarner C, Durandez R, et al. Randomized, multicenter, controlled trial comparing oral norfloxacin vs intravenous ceftriaxone in the prevention of bacterial infections in cirrhotics with severe liver failure and gastrointestinal bleeding. J Hepatol 2005;42[S2]:4.
27. Liu Q, Ping Duan Z, Kang Ha D, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-9.